Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMO | Q99835 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 7/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.37 |
| ▸ | ATF4 | P18848 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 6/20 | 0.36 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.36 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.36 |
| ▸ | SYK | P43405 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12825055 | 0.93 | SMO (0.44) | SMOEPHX2SYK | |
| SCHEMBL12824862 | 0.93 | SMO (0.44) | SMOEPHX2HSD17B10SYK | |
| SCHEMBL12825057 | 0.93 | SMO (0.44) | SMOEPHX2HSD17B10SYK | |
| SCHEMBL12824720 | 0.93 | SMO (0.44) | SMOEPHX2HSD17B10ENPP2SYK | |
| SCHEMBL12824594 | 0.92 | SMO (0.43) | SMOEPHX2KDM4EHPGDCNR2 | |
| SCHEMBL12825019 | 0.92 | SMO (0.44) | SMOEPHX2 | |
| SCHEMBL12824858 | 0.91 | SMO (0.45) | SMOEPHX2ENPP2SYK | |
| SCHEMBL12825022 | 0.89 | SMO (0.43) | SMOEPHX2HSD17B10 | |
| SCHEMBL12825027 | 0.89 | SMO (0.43) | SMOCNR1EPHX2ATF4KDM4E | |
| SCHEMBL12824713 | 0.89 | SMO (0.43) | SMOEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011024869-A1 | FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF | 武田薬品工業株式会社 (JP) | 2011-03-03 | — | — | WO | disclosed |